- Home
- GNTA
GNTA
Genenta Science S.p.A.
as 04-25-2025 4:00pm EST
| Founded: | 2014 | Country: | Italy |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $25.00 | AVG Volume (30 days): | 7.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.49 - $7.28 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Genenta Science S.p.A. News
GNTA Breaking Stock News: Dive into GNTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MT Newswires
a month ago
Genenta Science Obtains $21.9 Million Financing to Expand Pipeline
GlobeNewswire
a month ago
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
Simply Wall St.
2 months ago
February 2025 US Penny Stocks With Promising Prospects
Insider Monkey
2 months ago
Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?
PR Newswire
3 months ago
TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Simply Wall St.
3 months ago
3 Penny Stocks In US With Market Caps Below $300M
TipRanks
4 months ago
Genenta Science announces amendment to pact with AGC Biologics
Compare GNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNTA Genenta Science S.p.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.